CDX Stock Overview
Designs, manufactures, and markets medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CardieX Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.054 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.045 |
| Beta | 1.6 |
| 11 Month Change | -10.00% |
| 3 Month Change | -8.47% |
| 1 Year Change | -65.16% |
| 33 Year Change | -91.15% |
| 5 Year Change | -82.00% |
| Change since IPO | -99.23% |
Recent News & Updates
Shareholder Returns
| CDX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -10.0% | -3.4% | -1.3% |
| 1Y | -65.2% | 7.8% | 10.4% |
Return vs Industry: CDX underperformed the Australian Medical Equipment industry which returned 7.8% over the past year.
Return vs Market: CDX underperformed the Australian Market which returned 10.4% over the past year.
Price Volatility
| CDX volatility | |
|---|---|
| CDX Average Weekly Movement | 11.6% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CDX's share price has been volatile over the past 3 months.
Volatility Over Time: CDX's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Craig Cooper | cardiex.com |
CardieX Limited designs, manufactures, and markets medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that measures arterial health by collecting digital vascular biomarkers using novel sensors. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables for home health, decentralized clinical trials, and remote patient monitoring.
CardieX Limited Fundamentals Summary
| CDX fundamental statistics | |
|---|---|
| Market cap | AU$15.89m |
| Earnings (TTM) | -AU$7.64m |
| Revenue (TTM) | AU$12.40m |
1.3x
P/S Ratio-2.1x
P/E RatioIs CDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDX income statement (TTM) | |
|---|---|
| Revenue | AU$12.40m |
| Cost of Revenue | AU$797.87k |
| Gross Profit | AU$11.60m |
| Other Expenses | AU$19.24m |
| Earnings | -AU$7.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 93.57% |
| Net Profit Margin | -61.60% |
| Debt/Equity Ratio | 100.7% |
How did CDX perform over the long term?
See historical performance and comparison